Dr Paul White
Drug Discovery Biology
Associate Dean (Education)
Phone: +61 3 9903 9074
Dr White is a cardiovascular pharmacologist. He has published papers in high impact journals including Nature Medicine, PNAS, Molecular Pharmacology, Molecular Pharmaceutics, Journal of Medicinal Chemistry. He has supervised 7 PhD students to completion as primary supervisor. He has attracted funding from a variety of industry sources, National Heart Foundation and Nanotechnology Victoria. His main area of interest is the development of cardioprotective agents for patients who have suffered a myocardial infarction. Dr White, along with Dr Lauren May, Professors Arthur Christopoulos and Peter Scammells, lead a group developing novel adenosine receptor ligands for post MI patients.
1. Valant C, May LT, Aurelio L, Chuo CH, White PJ, Baltos JA, Sexton PM, Scammells PJ, Christopoulos A. Separation of on-target efficacy from adverse effects through rational design of a bitopic adenosine receptor agonist. Proc Natl Acad Sci USA. 2014;111(12):4614-9.
2. Lau S, Graham B, Cao N, Boyd BJ, Pouton CW, White PJ. Enhanced extravasation, stability and in vivo cardiac gene silencing via in situ siRNA-albumin conjugation. Molecular Pharmaceutics. 2012;9(1):71-80.
3. Hausler NE, Devine SM, McRobb FM, Warfe L, Pouton CW, Haynes JM, , White PJ* & Scammells PJ*. Synthesis and pharmacological evaluation of dual acting antioxidant A(2A) adenosine receptor agonists. Journal of Medicinal Chemistry. 2012; 55(7): 3521-34.
4. Urmaliya VB, Pouton CW, Ledent C, Short JL, White PJ. Cooperative cardioprotection through adenosine A1 and A2A receptor agonism in ischemia-reperfused isolated mouse heart. Journal of Cardiovascular Pharmacology. 2010;56(4):379-88.
5. Urmaliya VB, Pouton CW, Devine SM, Haynes JM, Warfe L, Scammells PJ, White PJ. A novel highly selective adenosine A1 receptor agonist VCP28 reduces ischemia injury in a cardiac cell line and ischemia-reperfusion injury in isolated rat hearts at concentrations that do not affect heart rate. Journal of Cardiovascular Pharmacology. 2010;56(3):282-92. Epub 2010/06/24.
6. Wraight CJ. White PJ, McKean SC, Fogarty RD, Venables DJ, Liepe IJ, Edmondson SR, Werther GA. Reversal of epidermal hyperproliferation in psoriasis by insulin-like growth factor I receptor antisense oligonucleotides. Nat Biotechnol. 2000;18:521-6.